Constellation Pharmaceuticals

PharmaShots’ Key Highlights of Second Quarter 2021

The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply agreement with US Government for Molnupiravir to treat COVID-19 The big acquisition took place during the quarter including Microsoft acquired Nuance for ~$19.7B, MorphoSys acquired Constellation for ~$1.7B Our team …

PharmaShots’ Key Highlights of Second Quarter 2021 Read More »

MorphoSys to Acquire Constellation Pharmaceuticals for ~$1.7B

Shots: MorphoSys to acquire all of the outstanding shares of Constellation’s common stock for $34.00/ share in cash making a total equity value of $1.7B. The transaction is expected to close in Q3’21 The acquisition will bolster Morphosys’ position in hematology-oncology & accelerates growth strategy with the addition of Constellation’s Pelabresib (CPI-0610) & CPI-0209 Additionally, …

MorphoSys to Acquire Constellation Pharmaceuticals for ~$1.7B Read More »

MorphoSys offers $1.7bn for Constellation, but investors see stars

Shares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to buy its US rival Constellation Pharma and its pipeline of cancer and haematology therapies. MorphoSys said the $34 per share deal would accelerate growth by adding two clinical-stage drug candidates, namely BET inhibitor pelabresib (CPI-0610) in phase …

MorphoSys offers $1.7bn for Constellation, but investors see stars Read More »

MorphoSys to buy Constellation Pharma in a $1.7B bet on epigenetic cancer drugs

MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma.